Castellani Says PhRMA Looking to Uphold Affordable Care Act to Protect Regulatory Pathway

Posted 13 April 2012 | By

The Pharmaceutical Research and Manufacturers of America was an early-and controversial-supporter of the Patient Protection and Affordable Care Act (PPACA) when the legislation was being formulated. Now under the tutelage of President John Castellani, the group says it is looking to keep the legislation in place, reports Market Watch.

The loss of a regulatory pathway for approving biosimilar products, said Castellani, would be a disastrous setback. Likewise a number of benefits and rebates under Medicare Part D would have to be renegotiated, explained Castellani.

"If it's struck down, then it all has to be reconstructed," remarked Castellani.

"The Supreme Court decision is very important but if you look over a long period of time… the fiscal condition of the country is going to force Congress to look at a whole set of the issues that are encompassed in the Affordable Care Act," said Castellani.

Read more:

Market Watch - Big Pharma not big on scrapping health-care reform


Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles